欢迎来到OAJRC平台！

期刊栏目

投稿

审稿

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据：

当前位置：国际外科研究杂志 > 2024年 7卷 (1)期

Open Access Article

International Journal of Surgical Research. 2024; 7: (1) ; 1-7 ; DOI: 10.12208/j.ijsr.20240001.

Association between remnant cholesterol and sarcopenia: A study based on the NHANES population
残余胆固醇与肌少症的关联：一项基于NHANES人群的研究

作者： 林洁^1,2, 庞永奎¹, 周文青¹, 鲁星妍¹, 金娟¹, 邱爱娟³, 任骏², 邱爱明¹ *

1 苏州市吴江区第五人民医院老年病科江苏苏州

2 复旦大学附属中山医院心内科，上海市心血管研究所上海

3 苏州市吴江区中医医院江苏苏州

*通讯作者：邱爱明,单位：苏州市吴江区第五人民医院老年病科江苏苏州；

吴江区科教兴卫项目（WWK202324）

发布时间: 2024-12-13 总浏览量: 167

PDF 全文下载引用本文

摘要

目的本文拟通过分析美国国家健康与营养检查调查（NHANES）2017至2018年的数据，评估残余胆固醇（RC）与肌少症患病率之间的相关性。方法本研究共纳入987名成年人，肌少症的评估基于骨骼肌质量与体重指数的比值。残余胆固醇由血脂数据计算得出。采用多变量回归模型分析残余胆固醇与肌少症之间的相关性，并利用接收者操作特征（ROC）曲线评估其预测准确性。结果高水平的残余胆固醇与肌少症高患病风险呈正相关。特别是在残余胆固醇4分位数组中，随着残余胆固醇水平升高，肌少症的患病风险显著增加。ROC曲线分析进一步证实RC具有较好的诊断效力，曲线下面积为0.713（95% CI：0.654-0.771），敏感性为76.2%，特异性为65.4%。结论高残余胆固醇水平与肌少症的高患病率显著相关，控制人群的残余胆固醇在低水平可能成为预防肌少症的有效干预措施。

关键词： 肌少症；残余胆固醇；横断面研究

Abstract

Objective This study aims to assess the correlation between remnant cholesterol (RC) and the prevalence of sarcopenia by analyzing data from the National Health and Nutrition Examination Survey (NHANES) from 2017 to 2018.
Methods A total of 987 adults were included in this study, and sarcopenia was assessed based on the ratio of skeletal muscle mass to body mass index. RC was calculated from lipid data. Multivariate regression models were used to analyze the correlation between RC and sarcopenia, and their predictive accuracy was assessed using Receiver Operating Characteristic (ROC) curves.
Results High levels of RC were positively associated with a high risk of sarcopenia. In particular, in the RC quartile 4 group, the risk of prevalence of sarcopenia increased significantly with higher levels of RC. ROC curve analysis further confirmed the good diagnostic validity of RC with an area under the curve of 0.713 (95% CI: 0.654-0.771), a sensitivity of 76.2% and a specificity of 65.4%.
Conclusion High RC levels are significantly associated with a high prevalence of sarcopenia, and controlling RC at low levels in the population may be an effective intervention to prevent sarcopenia.

Key words： Sarcopenia; Remnant cholesterol; Cross-sectional study

参考文献 References

[1] Cruz-Jentoft A J, Sayer A A. Sarcopenia [J]. Lancet, 2019, 393(10191): 2636-46.

[2] Haase C B, Brodersen J B, Bülow J. Sarcopenia: early prevention or overdiagnosis? [J]. BMJ, 2022, 376: e052592.

[3] Dennison E M, Sayer A A, Cooper C. Epidemiology of sarcopenia and insight into possible therapeutic targets [J]. Nat Rev Rheumatol, 2017, 13(6): 340-7.

[4] Al Saedi A, Debruin D A, Hayes A, et al. Lipid metabolism in sarcopenia [J]. Bone, 2022, 164: 116539.

[5] Buchmann N, Fielitz J, Spira D, et al. Muscle Mass and Inflammation in Older Adults: Impact of the Metabolic Syndrome [J]. Gerontology, 2022, 68(9): 989-98.

[6] Kawai T, Autieri M V, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity [J]. Am J Physiol Cell Physiol, 2021, 320(3): C375-C91.

[7] Hauck A K, Bernlohr D A. Oxidative stress and lipotoxicity [J]. J Lipid Res, 2016, 57(11): 1976-86.

[8] Hill M A, Yang Y, Zhang L, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease [J]. Metabolism, 2021, 119: 154766.

[9] Stürzebecher P E, Katzmann J L, Laufs U. What is 'remnant cholesterol'? [J]. Eur Heart J, 2023, 44(16): 1446-8.

[10] Damluji A A, Alfaraidhy M, AlHajri N, et al. Sarcopenia and Cardiovascular Diseases [J]. Circulation, 2023, 147(20): 1534-53.

[11] Tada H, Nohara A, Inazu A, et al. Remnant lipoproteins and atherosclerotic cardiovascular disease [J]. Clin Chim Acta, 2019, 490: 1-5.

[12] Li N. Platelets as an inter-player between hyperlipidaemia and atherosclerosis [J]. J Intern Med, 2024, 296(1): 39-52.

[13] Toth P P. Insulin resistance, small LDL particles, and risk for atherosclerotic disease [J]. Curr Vasc Pharmacol, 2014, 12(4): 653-7. DOI:

[14] Miller Y I, Shyy J Y J. Context-Dependent Role of Oxidized Lipids and Lipoproteins in Inflammation [J]. Trends Endocrinol Metab, 2017, 28(2): 143-52.

[15] Linton M F, Yancey P G, Tao H, et al. HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy [J]. Circ Res, 2023, 132(11): 1521-45.

[16] Nicholls S J, Nelson A J. HDL and cardiovascular disease [J]. Pathology, 2019, 51(2): 142-7.

[17] Jin J, Hu X, Francois M, et al. Association between remnant cholesterol, metabolic syndrome, and cardiovascular disease: post hoc analysis of a prospective national cohort study [J]. Eur J Med Res, 2023, 28(1): 420.

[18] Wadström B N, Pedersen K M, Wulff A B, et al. Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality [J]. Eur Heart J, 2023, 44(16): 1432-45.

[19] Castañer O, Pintó X, Subirana I, et al. Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease [J]. J Am Coll Cardiol, 2020, 76(23): 2712-24.

[20] Sandesara P B, Virani S S, Fazio S, et al. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk [J]. Endocr Rev, 2019, 40(2): 537-57.

[21] Wu Y, Wei Q, Li H, et al. Association of remnant cholesterol with hypertension, type 2 diabetes, and their coexistence: the mediating role of inflammation-related indicators [J]. Lipids Health Dis, 2023, 22(1): 158.

[22] Vargas-Vázquez A, Fermín-Martínez C A, Antonio-Villa N E, et al. Insulin resistance potentiates the effect of remnant cholesterol on cardiovascular mortality in individuals without diabetes [J]. Atherosclerosis, 2024: 117508.

[23] Varbo A, Nordestgaard B G. Remnant lipoproteins [J]. Curr Opin Lipidol, 2017, 28(4): 300-7.

引用本文

林洁, 庞永奎, 周文青, 鲁星妍, 金娟, 邱爱娟, 任骏, 邱爱明, 残余胆固醇与肌少症的关联：一项基于NHANES人群的研究[J]. 国际外科研究杂志, 2024; 7: (1) : 1-7.

入驻平台

回到首页

搜索文章: